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The objective of this work was to characterize trends over time in urinary excretion of 4-(methylnitros-
amino)-1-(3-pyridyl)-1-butanol (NNAL) among cigarette smokers in the US. We identiﬁed 35 studies pre-
senting data that either reported, or could be converted to, common units of total urinary NNAL excretion
as pmol/mg creatinine. The studies spanned 18 years, reported urinary NNAL excretion estimates for 61
deﬁned populations, and included a combined total of 3941 study participants. Analyses show that uri-
nary NNAL excretion trends downward with study publication year, and the trend is statistically signif-
icant. The trend does not appear to be accounted for by a reduction in cigarettes smoked per day by study
participants over the same time period. This trend is consistent with reductions in tobacco speciﬁc nitro-
samine (TSNA) levels in both cigarette tobacco ﬁller and mainstream cigarette smoke observed over the
past decade and with efforts by the tobacco industry and the agricultural community to reduce levels of
TSNAs in tobacco and cigarette smoke.
 2013 The Authors. Published by Elsevier Inc.Open access under CC BY-NC-ND license.1. Introduction smokers over time. We gathered and analyzed available publishedTobacco speciﬁc nitrosamines (TSNAs) are a class of cigarette
smoke constituents believed to play a potential role in
smoking-related carcinogenesis (IARC, 2007). The TSNAs, 4-(meth-
ylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and N-nitrosonor-
nicotine (NNN), have received the greatest attention due to their
carcinogenic activity in animal studies. Both are classiﬁed by the
International Agency for Research on Cancer as carcinogenic to hu-
mans (Group 1), and both are on the US Food and Drug Administra-
tion list of harmful and potentially harmful constituents in tobacco
products and tobacco smoke (IARC, 2007; USDHHS, 2012).
We previously reported that TSNA levels have declined signiﬁ-
cantly in mainstream cigarette smoke over at least the last decade
(Appleton et al., 2013). The objective of this work was to
characterize trends in urinary excretion of 4-(methylnitrosami-
no)-1-(3-pyridyl)-1-butanol (NNAL) among cigarette smokers to
determine possible changes in exposure to TSNAs among cigarettedata on urinary NNAL excretion among cigarette smokers over an
18-year period. Total urinary NNAL (sum of NNAL and
NNAL-glucuronide) has been reported to be a speciﬁc biomarker
for exposure to NNK (Hecht, 2002) and has been widely used as
a biomarker indicative of TSNA exposure from cigarette smoking.
It has also been reported to be a biomarker of risk for lung cancer
(IARC, 2009).
2. Methods
We searched PubMed Central (US National Institutes of Health,
National Library of Medicine; http://www.ncbi.nlm.nih.gov/
pubmed) for published papers reporting urinary NNAL excretion
data in cigarette smokers. Studies were also identiﬁed as refer-
enced in reports identiﬁed in the PubMed search and from other
sources.
We used the following criteria for inclusion of studies identiﬁed
in the literature:
- Study was original research.
- Study reported urinary excretion of total NNAL (sum of NNAL
and NNAL-glucuronide).
- Study participants were adult cigarette smokers.
- Study conducted in the US of participants smoking US commer-
cial cigarettes.
- Cigarettes were smoked under natural conditions (no forced
smoking regimens).
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Published studies were examined to determine if a data set for
one or more deﬁned populations had been previously published. In
cases where a data set was clearly identiﬁed as having been previ-
ously published, the default approach was to use only the data
from the earliest publication. Because our objective was to com-
pare levels of urinary NNAL excretion from different studies over
time, the analysis was conﬁned to NNAL data that were either re-
ported as, or could be converted to, common units suitable for
comparison.
Urinary NNAL excretion estimates for different deﬁned popula-
tions (e.g., male vs. female, Black vs. White) that were reported
separately in the original publications were handled as separate
population estimates with no attempt to average or merge individ-
ual estimates. If both individual population estimates and an over-
all population estimate were presented, only the highest-order
population estimate was used in the analysis. In cases where only
individual subject data were presented, we calculated group
means. Likewise, in cases where values for NNAL and NNAL-glucu-
ronide were only presented separately as molar units, we calcu-
lated the sum of the two to obtain total NNAL.
The data were analyzed for trend with year of publication using
a general linear model in a standard statistical analysis software
package (IBM SPSS Statistics, Armonk, NY). In the primary analysis
the dependent variable of the model was NNAL level in pmol/mg
creatinine, and the covariates were study publication year and cig-
arettes per day (CPD). The data points were weighted by the num-
ber of study participants.3. Results
Our literature search identiﬁed 52 potentially relevant study
publications. Among these publications, a wide variety of units
were used to express urinary NNAL excretion. Twenty-nine of the
52 studies expressed urinary NNAL excretion as pmol/mg creati-
nine (Anderson et al., 2001; Benowitz et al., 2005, 2010b,
2012a,b; Carmella et al., 1995, 1997, 2003; Church et al., 2010;
Hatsukami et al., 2004, 2010; Hecht et al., 1995, 1999, 2007;
Hughes et al., 2004; Hurt et al., 2000; Joseph et al., 2005; Khariwala
et al., 2012; Le Marchand et al., 2008; Melikian et al., 2007; Men-
doza-Baumgart et al., 2007; Muscat et al., 2005, 2009; Sellers
et al., 2003; St. Helen et al., 2012; Stepanov and Hecht, 2005;
Strasser et al., 2011; Taioli et al., 1997; Ter-Minassian et al., 2012).
The rest of the studies expressed urinary NNAL excretion using a
variety of units. Six studies expressed urinary NNAL excretion as ng/
24 h: Frost-Pineda et al. (2008), Heck (2009), Kinser et al. (2002),
Roethig et al. (2008, 2009) and Sarkar et al. (2010). Five studies ex-
pressed urinary NNAL excretion as pg/mL urine: Benowitz et al.
(2010a), Bernert et al. (2010), Blank and Eissenberg (2010), Breland
et al. (2003) and Heck (2009). Four studies expressed urinary NNAL
excretion as pmol/mL urine: Derby et al. (2009), Hatsukami et al.
(2007),Murphy et al. (2004) and Stepanov et al. (2009). Four studies
expressed urinary NNAL excretion as nmol/24 h: Carmella et al.
(1993, 2009), Hecht et al. (1995) and Stepanov et al. (2008). Four
studies expressed urinary NNAL excretion as pg/mg creatinine:
Benowitz et al. (2010a), Goniewicz et al. (2009), Heck (2009) and
Rostron (2013). Two studies expressed urinary NNAL excretion as
ng/mL urine: Jones et al. (2013) and Stepanov et al. (2007). One
study expressed urinary NNAL excretion as ng/mg creatinine: Ash-
ley et al. (2010); and one study expressed urinary NNAL excretion
as ng/g creatinine: Sarkar et al. (2008).
To make valid comparisons of NNAL excretion data over time,
we wanted to use data expressed in common units. The most
frequently used unit of NNAL expression was pmol/mg creatinine.However, almost half of the studies used a variety of other units to
express urinary NNAL excretion. Therefore, in order to bring more
data into the primary analysis, we converted data from the studies
reporting NNAL excretion in units other than pmol/mg creatinine.
This resulted in the consolidation of data from nine different units
of NNAL expression into three: pmol/mg creatinine, nmol/24 h, and
pmol/mL urine. The vast majority of data spanning the longest pos-
sible time frame were data normalized to creatinine, namely,
pmol/mg creatinine. Therefore, NNAL excretion data expressed as
pmol/mg creatinine formed the basis of our primary analysis.
Table 1 presents characteristics of the 35 studies used in this
analysis. The publication of these studies covered a time span of
18 years from 1995 to 2012, inclusive. These studies collectively
reported urinary NNAL excretion estimates for 61 deﬁned study
populations involving a total of 3941 study participants. Fig. 1 is
a scatter plot of data for total NNAL excretion over time from the
61 study populations in which the data are expressed as pmol/
mg creatinine.
We initially analyzed the data without adjusting for CPD or
weighting the data by number of study participants, thus allowing
the use of all 61 study populations. The results show a statistically
signiﬁcant decline in urinary NNAL excretion with study publica-
tion year. The trend line is shown in Fig. 1. We conducted the pri-
mary analysis of data from the 51 study populations that also
reported CPD and number of study participants. The primary anal-
ysis shows that urinary NNAL excretion trends downward with
study publication year by 0.137 pmol/mg creatinine/year, and the
trend is statistically signiﬁcant (p < 0.00001). NNAL excretion
increased by 0.049 pmol/mg creatinine for each additional CPD,
and the increase was statistically signiﬁcant (p = 0.0002). The mod-
el explained much of the variance in the NNAL excretion levels
(adjusted R2 = 0.61).4. Discussion
The U. S. Surgeon General and others have stated that the role of
speciﬁc smoke constituents in smoking-related disease is currently
not known (Burns et al., 2008; USDHHS, 2010). Likewise, it is not
knownwhether reduction of TSNA exposure fromcigarette smoking
would result in a reduction in the risk of smoking-related disease.
Based on the analysis presented here, urinary NNAL excretion
among cigarette smokers appears to have been declining over the
period from 1995 to 2012. Given the utility of urinary NNAL excre-
tion as a speciﬁc biomarker for NNK exposure and a general marker
for TSNA exposure, the observed trend in urinary NNAL excretion
provides evidence of a downward trend in TSNA exposure from
cigarette smoking.
The downward trend in urinary NNAL excretion does not ap-
pear to be explained by reductions over time in CPD among study
participants. Although NNAL excretion is signiﬁcantly associated
with CPD, our primary analysis shows that the downward trend
of NNAL is statistically signiﬁcant over time independent of CPD.
Furthermore, we analyzed the data from all the study populations
and did not ﬁnd a statistically signiﬁcant downward trend of CPD
with study publication year. At ﬁrst glance, this may seem surpris-
ing given reports of a signiﬁcant decline in mean CPD among daily
smokers in recent years (MMWR, 2012). However, it must be kept
in mind that participant eligibility criteria for most of the studies
reviewed here included a requirement that a minimum number
of CPD were smoked (usually 10–15). Therefore, these studies are
not necessarily designed to be representative of contemporary
population smoking patterns. Nevertheless, they are still useful
for identifying trends in TSNA exposure over time that may be
reﬂective of changes in TSNA levels in cigarette smoke.
Table 1
Characteristics of studies expressing urinary NNAL excretion in US smokers as pmol/mg creatinine.
Report authors
(year of publication)
Study population characteristics Number of study
participants
Total urinary
NNAL
(pmol/mg
creatinine)
CPD
Carmella et al. (1995) Cross-sectional study of cigarette smokers 61 3.76 NR
Hecht et al. (1995) Baseline data from cigarette smokers before consumption of watercress 11 2.67 14.8
Carmella et al. (1997) Cross-sectional study of cigarette smokers 18 3.8 NR
Taioli et al. (1997) Cross-sectional study of female cigarette smokers 13 3.9 15.2
Hecht et al. (1999) Baseline data from cigarette smokers before assignment to smoking cessation groups 27 2.7 23.7
Hurt et al. (2000) Baseline data of ‘‘heavy’’ cigarette smokers before treatment with a nicotine inhaler 18 3.69 41.9
Anderson et al. (2001) Cross-sectional study of cigarette smokers 23 1.7 25
Carmella et al. (2003) Cross-sectional study of cigarette smokers 41 2.6 NR
Sellers et al. (2003) Baseline data from cigarette smokers before treatment with methoxsalen 11 1.34 22.6
Hatsukami et al. (2004) Baseline data from cigarette smokers before switching to OMNI cigarettes 22 2.2 21.7
Hughes et al. (2004) Baseline data from cigarette smokers before switching to OMNI cigarettes 34 3.5 30
Benowitz et al. (2005) Baseline data from cigarette smokers before switching to ‘‘light’’ cigarettes 16 2.3 22.5
Joseph et al. (2005) Baseline data from participants enrolled in a smoking reduction clinical trial; Cohort 1
(TRIP)
151 2.2 24.2
Baseline data from participants enrolled in a smoking reduction clinical trial; Cohort 2
(ROSCAP)
152 2.7 27.5
Cross-sectional data from ‘‘light’’ smokers; Cohort 3 (ACSS) 86 1.2 9.2
Cross-sectional data from ‘‘light’’ smokers; Cohort 4 (LLSS) 11 2.2 8.5
Muscat et al. (2005) Cross-sectional study of Black male cigarette smokers 28 2.6 16.7
Cross-sectional study of White male cigarette smokers 47 1.9 23.7
Cross-sectional study of Black female cigarette smokers 41 2.7 14
Cross-sectional study of White female cigarette smokers 46 3.2 22
Stepanov and Hecht
(2005)
Cross-sectional study of cigarette smokers 14 1.53 NR
Hecht et al. (2007) Baseline data from participants enrolled in a smoking reduction study 186 2.62 24.7
Melikian et al. (2007) Cross-sectional study of cigarette smokers categorized as low-yield FTC nicotine group 87 1.75 16.3
Cross-sectional study of cigarette smokers categorized as medium-yield FTC nicotine
group
109 1.68 16.3
Cross-sectional study of cigarette smokers categorized as high-yield FTC nicotine group 61 1.21 16.3
Mendoza-Baumgart
et al. (2007)
Baseline data from cigarette smokers before crossover treatment with medicinal nicotine
lozenge to Exalt
19 1.32 21.8
Baseline data from cigarette smokers before crossover treatment with Exalt to medicinal
nicotine lozenge
20 1.58 20.8
Baseline data from cigarette smokers before crossover treatment with medicinal nicotine
lozenge to Ariva
12 0.98 20
Baseline data from cigarette smokers before crossover treatment with Ariva to medicinal
nicotine lozenge
14 1.02 21.7
Le Marchand et al.
(2008)
Cross-sectional study of cigarette smokers conducted in Hawaii 583 1.28 20
Cross-sectional study of cigarette smokers conducted at the University of Minnesota
(UMN Study 2)
137 0.91 20
Sarkar et al. (2008) Baseline data from cigarette smokers before switching to 11 mg FTC tar charcoal
cigarettes
20 1.45 17.9
Baseline data from cigarette smokers before switching to 6 mg FTC tar conventional
cigarettes
25 1.53 18
Baseline data from cigarette smokers before switching to 11 mg FTC tar conventional
cigarettes
20 1.69 18.5
Baseline data from cigarette smokers before switching to 6 mg FTC tar charcoal
cigarettes
50 1.65 18.5
Goniewicz et al. (2009) Cross sectional study of daily cigarette smokers 8 2.08 22.0
Heck (2009) Cross sectional study of menthol cigarette smokers 54 1.36 27
Cross sectional study of non-menthol cigarette smokers 58 2.09 27
Muscat et al. (2009) Cross-sectional study of menthol cigarette smokers 67 2.9 NR
Cross-sectional study of non-menthol cigarette smokers 80 3.2 NR
Ashley et al. (2010) Cross-sectional study of cigarette smokers from Minnesota 27 1.04 19.7
Cross-sectional study of cigarette smokers from New York 24 1.39 18.3
Benowitz et al. (2010a) Cross-sectional study of regular and occasional cigarette smokers from San Francisco,
California
59 0.57 6.9
Cross-sectional study of regular and occasional cigarette smokers from Pittsburg,
Pennsylvania
130 1.07 18.4
Benowitz et al. (2010b) Cross-sectional study of menthol cigarette smokers 60 0.9 18.8
Cross-sectional study of non-menthol cigarette smokers 67 1.2 17
Church et al. (2010) Cross-sectional study of cigarette smokers 70 1.47 24.1
Hatsukami et al. (2010) Baseline data from cigarette smokers before switching to 0.3 mg FTC nicotine cigarettes 52 0.96 19.8
Baseline data from cigarette smokers before switching to 0.05 mg FTC nicotine cigarettes 53 0.92 21.1
Baseline data from cigarette smokers before switching to nicotine lozenge 60 1.06 21.3
Strasser et al. (2011) Cross-sectional study of cigarette smokers 109 1.47 20.5
Benowitz et al. (2012a) Baseline data from cigarette smokers assigned to control group 50 1 19
Baseline data from cigarette smokers assigned to progressive reduced nicotine content
group
53 1.4 22
Baseline data from cigarette smokers assigned to progressive reduced nicotine content 42 1.3 22
(continued on next page)
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Table 1 (continued)
Report authors
(year of publication)
Study population characteristics Number of study
participants
Total urinary
NNAL
(pmol/mg
creatinine)
CPD
group in those who complied
Benowitz et al. (2012b) Cross-sectional study of Alaskan Native cigarette smokers 163 0.89 7.8
Khariwala et al. (2012) Cross-sectional study of cigarette smokers who were head and neck squamous cell
carcinoma cases
29 1.51 NR
Cross-sectional study of cigarette smokers who were head and neck squamous cell
carcinoma controls
100 1.68 NR
Rostron Cross-sectional study of menthol cigarette smokers NR 1.28 14
Cross-sectional study of non-menthol cigarette smokers NR 1.84 17.5
St. Helen et al. (2012) Cross-sectional study of US smokers 225 1.05 19.4
Ter-Minassian et al.
(2012)
Cross-sectional study of current cigarette smokers 87 1.41 20
ACSS, Adult Cross-sectional Study; CPD, cigarettes per day; FTC, Federal Trade Commission; LLSS, Low Level Smoking Study; NNAL, 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanol; NR, not reported; ROSCAP, Reduction of Smoking in Cardiac Patients Study; TRIP, Tobacco Reduction Intervention Program.
Fig. 1. Scatter plot of urinary NNAL excretion in US smokers expressed as pmol/mg
creatinine, vs. year of publication showing a statistically signiﬁcant downward
trend (solid line, p < 0.00001).
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several limitations. The analysis did not include data from all
published studies that met our inclusion criteria. Rather, it
was limited to the largest body of data that either reported,
or could be converted to, common units of NNAL excretion.
Nevertheless, the analysis still included a substantial amount
of data from 3941 study participants, 61 deﬁned populations,
and published in 35 studies over an 18-year period. To address
this limitation, we plotted NNAL excretion data from studiesFig. 2. Scatter plot of urinary NNAL excretion in US smokers expressed as nmol/
24 h and pmol/mL urine vs. year of publication showing statistically signiﬁcant
downward trends (dotted line, nmol/24 h, p = 0.002; solid line, pmol/mL, p = 0.003).identiﬁed in our literature search that either reported, or could
be converted to common units of NNAL excretion as nmol/24 h,
or pmol/mL urine. A scatter plot of those data vs. year of study
publication is presented in Fig. 2 along with the statistically sig-
niﬁcant trend lines showing a decline of NNAL over time. It
must be noted that the interpretive value of these data sets is
limited by either very few data points, relatively short time
spans across studies, or both. Another limitation of this analysis
is that the years the studies were published are unlikely to be
the same as the years that the urine samples were collected.
Unfortunately, few of the studies in this survey presented sam-
ple collection dates. Since the analysis reported here includes
data generated across multiple laboratories, using various ana-
lytical methods and data reporting conventions, involving multi-
ple demographic groups, and spanning 18 years, it is not
possible to identify or control all potential sources of bias or
confounding that may have inﬂuenced the ﬁndings in one direc-
tion or the other. The extent to which urinary NNAL excretion
data for a particular population had been previously published
was not always clear from the information available in some
of the published reports. Therefore, we cannot be absolutely cer-
tain that our efforts to avoid using duplicate data did not result
in inclusion of some previously published data or exclusion of
some new data.
Despite these limitations, it is reasonable to expect that the
downward trend in urinary NNAL excretion observed in this
data set is reﬂective of a real phenomenon. For more than a
decade, US tobacco companies and the agricultural community
have actively researched the fundamental science related to
TSNA formation, TSNA levels in tobacco and tobacco smoke,
and methods to reduce these levels. These efforts have resulted
in changes in tobacco curing practices as well as other measures
intended to reduce TSNA levels in tobacco products (Appleton
et al., 2013). Evidence suggests that progress toward this goal
is being made. We recently reported that TSNA levels in ciga-
rette smoke have been declining for a number of years, and par-
ticularly in the past decade. We also presented evidence that
TSNA levels in cigarette tobacco ﬁller have been declining over
the past decade (Appleton et al., 2013).
Ashley et al. (2010) measured mouth-level exposure to NNK
and urinary concentrations of NNAL in 126 daily smokers in four
countries. The investigators reported that smoking cigarettes
with lower TSNA emissions results in lower internal dose levels
of NNAL. They further concluded that reducing the levels of NNK
in mainstream cigarette smoke through curing practices can
signiﬁcantly affect a smoker’s exposure to this constituent. Thus,
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is consistent with the ﬁndings of Ashley et al. (2010) as well
as evidence indicating that TSNA levels have been declining in
both cigarette tobacco ﬁller and cigarette smoke for at least
the past 10 years.
In conclusion, an analysis of total urinary NNAL excretion data
among 3941 study participants reported in 35 studies published
over 18 years suggests that exposure to TSNAs has declined among
cigarette smokers over that time period. These ﬁndings are consis-
tent with various efforts to reduce TSNA levels in tobacco products
as well as observed reductions in TSNA levels in cigarette tobacco
and smoke over the same time period.5. Funding sources
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